Key takeaways
View moreDespite strong operational performance and growth prospects, UnitedHealth Group's current valuation appears moderately overvalued given significant near-term headwinds from Medicare Advantage utilization spikes and regulatory pressures. The EV/Sales ratio of 1.4x versus industry average of 0.79x, combined with liquidity concerns and rising medical costs, suggests the current price doesn't adequately discount these risks, even considering the company's superior ROE and market position.
- UnitedHealth Group's revenue continues to grow, reaching $109.58 billion in Q1 2025, but profitability is under pressure due to rising medical costs, particularly in the Medicare Advantage segment, leading to a revised EPS outlook of $26-$26.50.
- The company's liquidity position is concerning, with a current ratio of 0.85 in Q1 2025, below the industry average, indicating potential short-term financial challenges.
- UNH's debt-to-equity ratio of 85.51% in Q1 2025, slightly above the industry average of 83.72%, raises concerns about its financial leverage and long-term solvency.
- Despite challenges, Optum Rx is experiencing strong growth, with revenues exceeding $35 billion in the last quarter, driven by customer retention and new customer wins, highlighting the importance of PBM services in reducing drug prices.
- Compared to the Health Care Select Sector SPDR Fund (XLV), UNH has significantly underperformed, with a YTD return of -38.08% versus XLV's -2.63%, indicating higher volatility and lower risk-adjusted returns.
- The earnings call highlighted a Medicare Advantage utilization spike, requiring immediate corrective actions, including engaging complex patients and investing in physician clinical workflow, to mitigate the impact on profitability.
- SEC filings reveal significant risks related to cybersecurity incidents and regulatory changes, particularly in Medicare Advantage and Medicaid programs, which could materially impact financial performance and operations.
- Management aims to return to its long-term earnings per share growth target of 13% to 16%, contingent on successful implementation of corrective actions and effective cost management.
- The Enterprise Value to Sales ratio of 1.4 is higher than the industry average of 0.79, suggesting that the company may be overvalued relative to its sales, warranting caution.
- UNH's recent stock price decline and underperformance compared to peers and benchmarks raise concerns about its current risk profile, requiring investors to closely monitor its performance and strategic adjustments.
Evaluation summary
Add to research
-
Company Overview:
- UnitedHealth Group, Inc. (UNH) operates as a diversified health care and well-being company. Its primary business segments are UnitedHealthcare and Optum. UnitedHealthcare offers health benefit plans and services for employers, individuals, and Medicare and Medicaid beneficiaries. Optum provides health services, including care delivery, pharmacy care services, data analytics, and technology solutions.
- Key products and services include risk-based health plans, value-based care arrangements, pharmacy benefits management, and health care technology and consulting. The company serves a wide range of customers, including employers, health plans, government programs, care providers, and life sciences companies.
- For comparative analysis, the company's performance is benchmarked against the Health Care Select Sector SPDR Fund (XLV) and industry peers Humana, Inc. (HUM), and Elevance Health, Inc. (ELV).
-
Financial Performance:
- UnitedHealth Group has demonstrated consistent revenue growth over the past year. Quarterly sales/revenue increased from $98.86 billion in Q2 2024 to $109.58 billion in Q1 2025. However, the rate of revenue growth appears to be decelerating.
- Net income has fluctuated, with a low of $4.22 billion in Q2 2024 and a high of $6.47 billion in Q1 2025. The company's profitability is influenced by factors such as medical costs, regulatory changes, and operational efficiency.
- The net profit margin has varied, ranging from 4.26% in Q2 2024 to 6.01% in Q3 2024. The net profit margin for the most recent quarter (Q1 2025) was 5.74%.
- Return on Average Assets (ROA) has increased from 4.98% in Q2 2024 to 7.44% in Q1 2025. Return on Average Total Equity (ROE) has also increased from 16.43% to 24.33% over the same period. Return on Average Total Capital has risen from 14.28% to 18.06%.
- Compared to the industry average, UnitedHealth Group's ROA (7.44%), ROE (24.33%), and Return on Average Invested Capital (13.95%) are significantly higher than the industry averages of -1.67%, -35.69%, and -19.65%, respectively, indicating superior profitability and efficiency in utilizing assets and capital.
- The earnings call highlighted a Medicare Advantage utilization spike, which is expected to negatively impact the company's financial performance in 2025, leading to a revised adjusted earnings per share outlook of $26-$26.50.
-
Operational Efficiency:
- Total assets have increased steadily, from $286.06 billion in Q2 2024 to $309.79 billion in Q1 2025, reflecting the company's growth and expansion. Total liabilities have also increased, from $186.82 billion to $204.62 billion over the same period.
- Working capital management appears to be a challenge, as the current ratio is below 1.0, indicating potential liquidity issues. The current ratio was 0.88 in Q2 2024 and decreased to 0.85 in Q1 2025.
- Net operating cash flow has fluctuated significantly, ranging from $2.37 billion in Q4 2024 to $13.95 billion in Q3 2024. In Q1 2025, net operating cash flow was $5.46 billion.
- Free cash flow to equity has also varied, from $1.46 billion in Q4 2024 to $12.95 billion in Q3 2024. In Q1 2025, free cash flow to equity was $4.56 billion. The free cash flow margin was 0.04 in Q1 2025.
- Total capital expenditure has remained relatively stable, ranging from $853 million in Q2 2024 to $991 million in Q3 2024. In Q1 2025, total capital expenditure was $898 million.
- The company has consistently returned capital to shareholders through dividends. Cash dividends paid were approximately $1.9 billion per quarter.
- The debt-to-equity ratio has fluctuated, ranging from 82.52% in Q3 2024 to 88.27% in Q4 2024. In Q1 2025, the debt-to-equity ratio was 85.51%. This is slightly above the industry average of 83.72%.
-
Growth Opportunities:
- UnitedHealth Group is focused on expanding its market presence through strategic initiatives, including growing its Medicare Advantage business and expanding Optum Health's value-based care arrangements.
- The company is investing in technology and innovation to improve operational efficiency and enhance customer engagement. Digital engagement among senior members has increased by more than 40%, leading to higher wellness visits.
- Optum Rx is experiencing strong growth, driven by new wins and high retention of long-term customers. Optum Rx will remove prior authorizations on 80 drugs, and payment models to pharmacies are being aligned more closely to their cost for drugs.
- UnitedHealthcare's Medicare Advantage business is on pace to serve an additional 800,000 people, and Optum Health is on track to add 650,000 net new patients to value-based care arrangements.
- The company's capital allocation strategies are aligned with its growth objectives, with investments in strategic initiatives and returns to shareholders through dividends and share repurchases.
-
Recent Developments and Market Sentiment:
- The earnings call on April 17, 2025, revealed a significant Medicare Advantage utilization spike, leading to a revised adjusted earnings per share outlook for 2025. This development has likely negatively impacted market sentiment.
- Management outlined specific actions to address the performance challenges, including engaging complex patients, consistent member engagement, health status assessments, and investments in physician clinical workflow.
- Analysts have raised concerns about Medicare Advantage cost trends, the relationship between primary care visits and Optum Health pressure, and the path to long-term growth rate.
- The SEC filings highlight the company's exposure to government investigations, audits, and legal proceedings, which could impact market sentiment.
-
Risks and Threats:
- A key risk is the ability to effectively estimate, price, and manage medical costs for risk-based products and services, particularly in the Medicare Advantage and Medicaid markets.
- Potential failures or disruptions to information systems and technology, including cybersecurity incidents, pose a significant threat to the company's operations and financial performance.
- Regulatory changes and uncertainties, especially around Medicare Advantage and Medicaid programs, could negatively impact the company's revenue and profitability.
- The company faces competition from a range of organizations, including startups, large enterprises, non-profits, and government entities.
- The SEC filings mention exposure to government investigations, audits, and legal proceedings, which could result in significant financial and reputational costs.
-
Valuation Analysis:
- The Enterprise Value to Sales ratio is 1.4, which is higher than the industry average of 0.79, suggesting that the company may be overvalued relative to its sales.
- The Enterprise Value to EBITDA ratio is not available for UNH, but the industry average is 10.45.
- Potential catalysts for the company's valuation include successful implementation of corrective actions to address the Medicare Advantage utilization spike and continued growth in Optum Rx and Optum Health.
-
Price Performance:
- UnitedHealth Group's stock price has experienced significant volatility in recent months. The price declined from approximately $401.96 on May 5, 2025, to $307.56 on July 2, 2025.
- Compared to the Health Care Select Sector SPDR Fund (XLV), UnitedHealth Group has significantly underperformed across most time periods. As of the Year To Date (YTD), UNH has a return of -38.08% compared to XLV's -2.63%.
- Compared to peers Humana (HUM) and Elevance Health (ELV), UNH has underperformed in the short term (Year-to-Date and 1 Year), but has shown better performance than Humana over longer periods (2 and 3 years).
-
Future Outlook:
- Management has revised the adjusted earnings per share outlook for 2025 to $26-$26.50 due to increased care activity in UnitedHealthcare's Medicare Advantage business and unanticipated changes in Optum Medicare membership.
- The company aims to return to its long-term earnings per share growth target of 13% to 16%.
- Analysts are closely monitoring Medicare Advantage cost trends, the impact of regulatory changes, and the company's ability to navigate these challenges.
-
Summary:
- UnitedHealth Group is a leading health care company with strong revenue growth and a diversified business model. However, the company faces significant challenges related to medical cost management, regulatory pressures, and cybersecurity risks.
- The company's strengths include its strong market position, diversified business segments, and commitment to innovation. Weaknesses include the Medicare Advantage utilization spike, potential liquidity issues, and increasing debt levels.
- Opportunities include expanding its market presence through strategic initiatives, leveraging technology to improve operational efficiency, and growing Optum Rx and Optum Health. Threats include regulatory changes, competition, and potential cybersecurity incidents.
- The company's financial health is mixed, with strong revenue growth but challenges related to profitability and liquidity. The company needs to address the Medicare Advantage utilization spike and improve cost management to sustain its growth trajectory.
- Critical factors for future performance include successful implementation of corrective actions, continued growth in Optum Rx and Optum Health, and effective management of regulatory and cybersecurity risks.
- Areas requiring further monitoring include Medicare Advantage cost trends, liquidity position, and debt levels.
- Overall, UnitedHealth Group presents a complex investment profile. While the company has strong growth potential and a leading market position, it faces significant challenges that could impact its financial performance. Investors should closely monitor the company's progress in addressing these challenges and consider the risks and opportunities before making investment decisions.
Price history
Add to research
Fundamentals
Add to research
Insights
- UnitedHealth Group demonstrates strong revenue growth and profitability, but faces challenges related to medical cost management, regulatory pressures, and cybersecurity risks.
- The company's liquidity position needs to be monitored closely, as the current ratio is below 1 and lower than the industry average.
- The increasing debt levels raise concerns about long-term solvency, requiring careful management of debt obligations.
- The Medicare Advantage utilization spike and patient profile shift in Optum Health pose significant challenges to profitability and require immediate and effective management.
- The company's ability to generate consistent cash flow is crucial for sustaining its growth and shareholder returns.
Analysis
- Revenue
- Revenue has shown a strong increasing trend, indicating robust growth in the company's core business operations.
- The growth in sales/revenue is decelerating, suggesting a need for continued innovation and market expansion to sustain high growth rates.
- The Enterprise Value to Sales ratio is higher than the industry average, indicating that the company may be overvalued relative to its sales.
- Profitability
- Profitability metrics, such as Return on Average Assets, Return on Average Total Equity, and Return on Average Total Capital, are strong and increasing, demonstrating the company's ability to generate profit.
- The Net Profit Margin is significantly higher than the industry average, indicating superior profitability.
- The Medicare Advantage utilization spike and patient profile shift in Optum Health, as noted in the earnings call, could pose challenges to profitability if not managed effectively.
- Liquidity
- The Current Ratio is below 1 and lower than the industry average, suggesting potential liquidity issues.
- The company needs to monitor its short-term obligations and ensure sufficient liquid assets to meet its liabilities.
- The SEC filings highlight the risk of potential failures or disruptions to information systems and technology, including cybersecurity incidents, which could impact liquidity.
- Solvency
- The Total Debt to Total Equity Ratio is increasing, indicating higher financial leverage.
- The company needs to manage its debt obligations carefully to maintain long-term solvency.
- The SEC filings mention exposure to government investigations, audits, and legal proceedings, which could impact solvency.
- Operational Efficiency
- The company demonstrates efficient revenue generation, as indicated by the growth in premium receivables.
- However, rising operating expenses suggest a need for better cost control measures to improve operational efficiency.
- The earnings call emphasizes the need for cost management and efficiency improvements to mitigate external pressures and return to long-term growth targets.
- Cash Flow Analysis - Cash flows from operations have fluctuated, with a recent increase, driven by net income and adjustments for non-cash items. - Free cash flow is expected to support debt repayment, dividend growth, and investment in organic growth opportunities. - The company's ability to generate consistent cash flow is crucial for sustaining its growth and shareholder returns.
- Risk Factors
- The company faces ongoing challenges around medical cost management, regulatory pressures (especially in Medicare Advantage and Medicaid), and technology/cybersecurity risks that could materially impact its financial performance and operations.
- The Medicare Advantage utilization spike and patient profile shift in Optum Health, as noted in the earnings call, pose significant challenges to profitability.
- The SEC filings highlight the risk of potential failures or disruptions to information systems and technology, including cybersecurity incidents, which could impact liquidity and operations.
- Future Outlook
- The company is projected to show continued revenue growth and profitability, driven by strategic initiatives and market expansion.
- However, the company needs to address the challenges related to medical cost management, regulatory pressures, and cybersecurity risks to sustain its growth trajectory.
- The earnings call emphasizes the need for corrective actions to address performance challenges and return to long-term earnings per share growth targets.
- Profitability
Financial statements
Add to research
Loading...
Public filings
Add to research
- UnitedHealth Group is a diversified health care leader with a strong market position across its Optum and UnitedHealthcare businesses, serving a wide range of customers including employers, health plans, government programs, and care providers.
- The company faces ongoing challenges around medical cost management, regulatory pressures (especially in Medicare Advantage and Medicaid), and technology/cybersecurity risks that could materially impact its financial performance and operations.
- UnitedHealth Group has demonstrated resilience in navigating industry disruptions, such as the Change Healthcare cyberattack, and continues to invest in growth initiatives, particularly within its Optum segment.
- The company's financial position remains strong, with robust cash flow generation and a disciplined approach to capital allocation, including dividends and share repurchases.
- Key risks to monitor include the company's ability to effectively price and manage medical costs, maintain critical stakeholder relationships, adapt to regulatory changes, and protect its technology infrastructure from cyber threats.
Core Business and Operations:
- UnitedHealth Group is a diversified health care and well-being company with two main business segments:
- Optum - Provides a range of health services including care delivery, population health management, data analytics, pharmacy care services, and technology solutions
- UnitedHealthcare - Offers a full suite of health benefit plans and services for employers, individuals, Medicare and Medicaid beneficiaries
- Key products and services include risk-based health plans, value-based care arrangements, pharmacy benefits management, data analytics, and health care technology and consulting
- Major customers include employers, health plans, government programs (Medicare, Medicaid), care providers, and life sciences companies
- Faces competition from a range of organizations including startups, large enterprises, non-profits, and government entities
Industry and Market Trends:
- Overall health care spending in the U.S. continues to grow due to factors like inflation, medical technology advancements, regulatory changes, and demographic trends
- Pricing and medical cost trends remain challenging, especially in the Medicare Advantage and Medicaid markets due to funding pressures and regulatory changes
- Industry is shifting towards value-based care models that aim to improve quality, affordability, and patient experience
- Regulatory environment is complex with various federal and state laws/requirements governing the health care sector
Recent Events:
- Completed the sale of its Brazil operations and initiated the sale of its remaining South American operations
- Experienced significant business disruption and incurred substantial costs due to the 2024 Change Healthcare cyberattack
- Continued to invest in and expand its Optum business, including care delivery, data/analytics, and pharmacy services
Risk Factors:
- Ability to effectively estimate, price, and manage medical costs for risk-based products and services
- Potential failures or disruptions to information systems and technology, including cybersecurity incidents
- Inability to maintain satisfactory relationships with health care providers, payers, and other key stakeholders
- Exposure to government investigations, audits, and legal proceedings
- Regulatory changes and uncertainties, especially around Medicare Advantage and Medicaid programs
- Macroeconomic conditions and their impact on demand for products/services and funding for government programs
Legal Matters:
- Involved in various governmental investigations, audits, and legal proceedings related to business practices, coverage determinations, and compliance matters
- Ongoing DOJ lawsuit alleging improper risk adjustment submissions, with the court recently recommending summary judgment in the company's favor
Management's Discussion and Analysis:
- Consolidated revenues grew 8% in 2024, driven by Optum Rx, UnitedHealthcare's domestic offerings, and Optum Health
- Earnings from operations were relatively flat year-over-year, impacted by the Change Healthcare cyberattack and other factors
- Medical cost trends increased due to elevated utilization, coding intensity, and specialty drug costs, partially offset by cost management efforts
- Strong cash flow generation, with $24.2 billion in operating cash flow for 2024
- Continued to return capital to shareholders through dividends and share repurchases
Earnings calls
Add to research
Earnings Report 2025Q1 (2025-04-17)
Key takeaways
- Medicare Advantage Utilization Spike is a Key Concern: The unexpected surge in care activity within the Medicare Advantage segment, particularly physician and outpatient services, poses a significant challenge to profitability and requires immediate and effective management.
- Optum Health's Patient Profile Shift Requires Adjustment: The influx of new patients into Optum Health with lower engagement levels and higher acuity necessitates operational adjustments and enhanced engagement strategies to improve reimbursement and manage costs effectively.
- Value-Based Care Model Remains a Core Strategy: Despite current headwinds, the company remains committed to its value-based care model, viewing it as a long-term solution for improving healthcare outcomes and controlling costs, but needs to adapt to pricing pressures.
- External Factors Significantly Impact Performance: Medicare funding cuts, CMS risk model changes, and potential pharmaceutical tariffs are creating significant external pressures that require proactive management and strategic adaptation.
- Cost Management and Efficiency are Critical: The company's focus on operating cost containment and leveraging technology to improve efficiency is essential for mitigating external pressures and returning to its long-term growth targets.
Focus of management’s prepared remarks
- Revised 2025 Outlook: Management revised the adjusted earnings per share outlook to $26-$26.50 due to increased care activity in UnitedHealthcare's Medicare Advantage business and unanticipated changes in Optum Medicare membership.
- Care Activity Increase: Care activity in UnitedHealthcare's Medicare Advantage business increased at twice the rate expected, primarily in physician and outpatient services.
- Optum Medicare Membership Changes: Unanticipated changes in Optum Medicare membership impacted 2025 revenue due to a lack of engagement from new patients covered by plans exiting markets and the impact of CMS risk model changes.
- Corrective Actions: Management outlined specific actions to address the performance challenges, including engaging complex patients, consistent member engagement, health status assessments, and investments in physician clinical workflow.
- Growth and Innovation: Despite the performance challenges, UnitedHealthcare's Medicare Advantage business is on pace to serve an additional 800,000 people, and Optum Health is on track to add 650,000 net new patients to value-based care arrangements.
- Optum Rx Performance: Optum Rx is experiencing strong growth, driven by new wins and high retention of long-term customers, underscoring the role of PBMs in reducing drug prices.
- Digital Engagement: New tools have sparked a more than 40% increase in digital engagement among senior members, leading to higher and earlier wellness visits.
- HouseCalls Program: The HouseCalls program in Medicare Advantage provides in-home clinical visits, helping to close care gaps and reduce hospital and emergency department visits.
- Initiatives for Simplicity and Affordability: Optum Rx will remove prior authorizations on 80 drugs, and payment models to pharmacies are being aligned more closely to their cost for drugs.
- Commitment to Transparency and Affordability: Management reiterated its commitment to transparency and affordability, highlighting the high cost of healthcare in the U.S. compared to other countries.
Focus of the analyst Q&A
- Medicare Advantage Cost Trends:
- What was the precise trend estimate assumed at the beginning of the year?
- What trend is now expected?
- How much did the first quarter MLR miss the company's own estimate?
- How different are the back three quarters expected to be versus the first quarter?
- Relationship Between Primary Care Visits and Optum Health Pressure:
- Why is higher follow-through expected if primary care is controlled?
- Why can costs be controlled better in a value-based care environment?
- What is the rationale for allocating more capital to value-based care?
- Drivers of Elevated Care on the MA Side:
- Is most of the elevated care being seen on the group side?
- Is this due to benefit and premium changes rather than an underlying uptick in utilization?
- Is the impact of competitive exits only on the Optum side?
- Is Part D performing as expected?
- Path to Long-Term Growth Rate:
- What are the key elements to get back to the long-term growth rate?
- MA Margins and Timeline for Recovery:
- Where are MA margins now expected to shake out inside the 2025 guidance?
- What is a reasonable timeline for recovering target margins?
- Is there any change to the long-term margin target in this business post V28?
- How confident is the company that it can improve margins in 2026 if trends stay at this level?
- PBM Reform and Medicaid Funding Cuts:
- What is the latest thinking in terms of PBM reform?
- What sort of permutations could be anticipated for Medicaid funding cuts?
- What is the company's ability to navigate these changes?
- Risks and Implications of Tariffs:
- What are the risks and implications of tariffs, particularly around pharmaceutical tariffs?
- Medicaid State Renewals:
- What is the update on state renewals through April?
- Is the company still on track to close the rate acuity gap by the end of the year?
- First Quarter MLR Impacts:
- What were the impacts driven by premium increases and deductible increases?
- Were there impacts as a result of changes in prior authorization?
- Was there increased follow-through from house calls and primary care actions tied to risk adjustment activity?
- Were there any one-time gains in the first quarter that supported the medical loss ratio?
- Impact of IRA on Pharma Manufacturers:
- Are the penalties under the IRA for pharma manufacturers who raise prices above inflation enough to protect the company from tariff pass-through on Medicare?
- Does this apply to exchanges as well?
- Will states give flexibility to submit two versions of bids with and without tariffs?
- Growth in C-SNP Plans:
- What does C-SNP enrollment mean from an economic perspective for UHC in 2025 and over the long term?
Summary
-
Financial Performance
UnitedHealth Group revised its adjusted earnings per share outlook for 2025 to $26-$26.50, a significant downward revision that management termed "unacceptable." Approximately 50% of the expected earnings are anticipated in the first half of the year. Consolidated revenue outlook remains affirmed at $450 billion to $455 billion. The full year medical care ratio is now expected to be 87.5%, plus or minus 50 basis points. Optum Health's revenue outlook is $106 billion to $107 billion, with operating earnings of $6.2 billion to $6.4 billion. UnitedHealthcare's operating earnings outlook is updated to $16 billion to $16.5 billion.
-
Revenue Drivers
Revenue changes are driven by better-than-expected performance at UnitedHealthcare and Optum Rx, offsetting a reduced outlook at Optum Health. Optum Rx revenues grew 14%, exceeding $35 billion for the quarter, driven by customer retention and new customer wins, contributing to script growth of 3%. UnitedHealthcare's Medicare Advantage business is on pace to serve an additional 800,000 people this year. Optum Health is on track to add 650,000 net new patients to value-based care arrangements. Commercial self-funded membership increased by approximately 700,000 in the first quarter.
-
Profit Margins and Cost Management
The medical care ratio is expected to be 87.5% plus or minus 50 basis points, reflecting higher utilization across senior populations and the patient mix and revenue profile of Optum Health. Management is focused on operating cost containment to mitigate external pressures. Technology advances are expected to drive further operating efficiency. Pressure was largely contained within the senior business at UnitedHealthcare, where a sharp increase in care activities was observed.
-
Guidance and Outlook
The company reaffirmed its consolidated revenue outlook of $450 billion to $455 billion. Adjusted earnings per share outlook for 2025 was revised to $26 to $26.50. UnitedHealthcare expects to serve up to 800,000 more people in Medicare Advantage this year. Optum Health continues to expect to add 650,000 new value-based care patients this year. The company aims to return to its long-term earnings per share growth target of 13% to 16%.
-
Strategic Initiatives
Key initiatives include engaging complex patients in clinical and value-based programs, consistent member engagement, health status assessments for new patients, and investments in physician clinical workflow. Optum Rx will remove prior authorizations on 80 drugs. Optum Rx has aligned payment models to pharmacies more closely to their cost for drugs. AI is being used to direct consumer calls to the right advocate.
-
Management Commentary
Management expressed dissatisfaction with the current performance but emphasized the company's growth and foundation for improvement. They highlighted the importance of Medicare Advantage and value-based care. They also emphasized the need for transparency and affordability in healthcare. The CEO stated the company is committed to improving performance in the rest of 2025 and into 2026 and returning to its long-term earnings per share growth target.
-
Industry and Market Conditions
The company noted that healthcare costs more in the U.S. than it should, citing disparities in drug prices and the cost of common procedures. They also mentioned the impact of Medicare funding cuts and the recently released 2026 rate notice, which begins to reflect accelerating care cost trends. The company is also closely monitoring potential pharmaceutical tariffs.
Comparative analysis
Add to research
Benchmarks (as of 2025-06-17)
Health Care Select Sector SPDR Fund (XLV)
-
Performance Comparison:
- UnitedHealth Group (UNH) has significantly underperformed the Health Care Select Sector SPDR Fund (XLV) across most time periods. As of the Year To Date (YTD), UNH has a return of -38.08% compared to XLV's -2.63%, indicating substantial underperformance. Over longer periods such as 1 year, 2 years, and 3 years, UNH has also underperformed XLV, with annualized returns of -34.58%, -17.48%, and -12.29% respectively, compared to XLV's -7.06%, 2.17%, and 4.4%. The only exception is the 1-week performance, where UNH slightly outperformed XLV.
-
Risk and Return Analysis:
- The annualized returns indicate that UNH has provided lower returns compared to XLV over the past 1, 2, and 3 years. Specifically, UNH's annualized returns are -34.58%, -17.48%, and -12.29%, while XLV's are -7.06%, 2.17%, and 4.4% respectively.
- UNH has generally exhibited higher annualized volatility compared to XLV. For example, in Q2 2025, UNH's volatility ranged from 72.75% to 98.76%, while XLV's ranged from 21.17% to 32.24%. This indicates that UNH's price fluctuations are more pronounced than those of XLV.
- UNH's maximum drawdown was -55.77% on 05/15/2025, significantly larger than XLV's maximum drawdown of -17.11% on 05/14/2025. This suggests that UNH carries a higher risk profile, with potential for more substantial declines from peak values.
-
Risk-Adjusted Performance:
- The Sharpe Ratio of UNH has generally been lower than that of XLV, indicating that UNH offers a less favorable risk-adjusted return. In Q2 2025, UNH's Sharpe ratio ranged from -1.22 to -0.76, while XLV's Sharpe ratio was higher, although also negative.
- UNH's Beta values have generally been below 1, suggesting that it is less sensitive to market movements compared to XLV. However, UNH's Beta has shown more variability, indicating an unstable relationship with the market.
-
Overall Assessment:
- Based on the data, UnitedHealth Group (UNH) has underperformed the Health Care Select Sector SPDR Fund (XLV) across most performance metrics. UNH exhibits higher volatility, larger drawdowns, and lower risk-adjusted returns compared to XLV. The recent trends indicate a significant decline in UNH's performance, with a severe drawdown and negative Sharpe Ratio in Q2 2025. These factors suggest that UNH carries a higher risk profile and has provided less favorable returns compared to the broader health care sector represented by XLV.
Peers Price History(as of 2025-06-17)
- Performance Comparison:
- UnitedHealth Group (UNH) has shown mixed performance compared to Humana (HUM) and Elevance Health (ELV). Over the past year, UNH has underperformed both HUM and ELV, with a 1-year return of -34.58% compared to HUM's -30.09% and ELV's -27.72%. However, over longer periods (2 and 3 years), UNH has outperformed HUM but underperformed ELV. For instance, UNH's 2-year return is -31.91%, better than HUM's -44.84% but worse than ELV's -11.87%. The recent underperformance is particularly evident in the year-to-date (YTD) return of -38.08%, significantly lagging behind HUM's -4.12% and ELV's 3.44%.
- Risk and Return Analysis:
- The annualized returns reflect a similar pattern. UNH's 1-year annualized return is -34.58%, underperforming HUM (-30.09%) and ELV (-27.72%). Over 2 and 3 years, UNH's annualized returns are better than HUM's but worse than ELV's. For example, UNH's 3-year annualized return is -12.29%, outperforming HUM's -17.95% but underperforming ELV's -5.37%.
- In terms of annualized volatility, UNH's volatility has generally been moderate compared to its peers. Humana (HUM) has shown higher volatility, especially in recent quarters, while Elevance Health (ELV) has maintained relatively stable volatility. For example, in Q1 2024, HUM's volatility ranged from 17.11% to 48.72%, while UNH's ranged from 17.05% to 23.81% and ELV's from 10.37% to 13.16%.
- The maximum drawdown for UNH was -55.77% on 05/15/2025, which is less than HUM's maximum drawdown of -59.09% on 05/23/2025, but significantly more than ELV's maximum drawdown of -34.48% on 01/02/2025. This indicates that UNH experienced substantial declines from its peak values, though not as severe as HUM.
- Risk-Adjusted Performance:
- UnitedHealth Group (UNH) generally exhibited higher Sharpe Ratios compared to Humana (HUM), indicating better risk-adjusted returns. However, Elevance Health (ELV) often showed comparable or even superior Sharpe Ratios, suggesting it also provided strong risk-adjusted performance.
- The beta values for UNH, HUM, and ELV were consistently below 1, indicating that these stocks were generally less volatile than the overall market. HUM generally had the lowest beta values, indicating it was the least sensitive to market movements among the three. ELV tended to have the highest beta values, suggesting it was slightly more responsive to market changes compared to UNH and HUM.
- Overall Assessment:
- UnitedHealth Group (UNH) has underperformed its peers, Humana (HUM) and Elevance Health (ELV), in the short term (Year-to-Date and 1 Year), but has shown better performance than Humana over longer periods (2 and 3 years). UNH's volatility has been moderate, and its risk-adjusted returns, as indicated by the Sharpe Ratio, have generally been better than Humana's but comparable to Elevance Health's. The beta values suggest that all three stocks are less volatile than the overall market, with Humana being the least sensitive and Elevance Health being the most sensitive.
- The recent underperformance of UNH, coupled with its high maximum drawdown, raises concerns about its current risk profile. However, its longer-term performance and moderate volatility suggest that it may still be a viable investment option, particularly if market conditions improve. Investors should closely monitor UNH's performance and consider the factors contributing to its recent underperformance before making investment decisions.
Peers Fundamentals(as of 2025-03-31)
-
Market Position and Size:
- UnitedHealth Group (UNH) stands out with a significantly larger market capitalization of $359,092.47 million compared to Humana (HUM) at $30,386.88 million and Elevance Health (ELV) at $93,532.57 million.
- This substantial market cap is supported by higher revenue ($410,057.0 million), net income ($22,106.0 million), and operating cash flow ($28,516.0 million) compared to its peers.
- UNH's dominance in size reflects its leading position in the managed healthcare industry.
-
Profitability and Efficiency:
- UNH's net profit margin of 5.39% is notably higher than HUM's 1.42%, ELV's 3.23%, and the industry average of -0.97%, indicating efficient operations and strong cost management.
- The Return on Average Assets for UNH is 7.44%, which is also higher than HUM (3.39%), ELV (5.11%), and the industry average (-1.67%), demonstrating superior efficiency in generating returns from its assets.
- However, UNH's Cash Conversion Ratio of 1.15 is lower than HUM (3.76) and ELV (2.15), suggesting it is less efficient at converting revenue into cash.
-
Financial Health and Stability:
- UNH's current ratio of 0.85 is lower than HUM (1.91), ELV (1.43), and the industry average (1.28), indicating potential liquidity concerns.
- Despite this, UNH's cash flow to total debt ratio of 31.64 is higher than HUM (23.94) and ELV (24.54) and significantly exceeds the industry average (-7.1), suggesting a strong ability to service its debt.
- Overall, UNH's strong cash flow generation provides some offset to its lower liquidity position.
-
Valuation and Market Perception:
- UNH's Enterprise Value to Sales ratio of 1.38 is higher than HUM (0.38), ELV (0.7), and the industry average (0.79), suggesting a premium valuation relative to sales.
- Its Price to Earnings ratio of 16.49 is lower than HUM (17.8) and the industry average (21.86), but slightly higher than ELV (16.15), indicating it may be relatively fairly valued compared to its earnings.
- The Price to Book Ratio for UNH is 3.9, which is less than the industry average of 4.13, but greater than HUM (1.71) and ELV (2.2).
-
Cash Flow and Capital Management:
- UNH's Net Operating Cash Flow ($28,516.0 million) and Free Cash Flow ($24,862.0 million) are significantly higher than HUM and ELV, demonstrating strong cash flow generation capabilities.
- This robust cash flow supports its market position and growth initiatives.
-
Growth and Future Prospect:
- UNH's net income growth shows significant year-to-year fluctuation, with a standard deviation of 25.89%.
- UNH shows superior growth in net income, free cash flow, and free cash flow margin compared to the peer group average.
- The most recent year-over-year growth rates for net income, free cash flow, and free cash flow margin are significantly higher than their respective 5-year CAGRs, indicating an acceleration in growth.
-
Potential for Investment:
- UNH presents an attractive investment opportunity due to its strong market position, superior profitability, robust cash flow generation, and efficient asset utilization.
- While its liquidity position and valuation metrics warrant consideration, its overall financial performance and growth potential make it a compelling investment choice within the managed healthcare industry.
-
Key Risks and Considerations:
- UNH's lower current ratio compared to peers and the industry average indicates potential liquidity risks.
- The high volatility in UNH's growth rates and the recent acceleration in net income, free cash flow, and free cash flow margin growth warrant further investigation to assess their sustainability.
-
Overall Assessment:
- UNH demonstrates strong financial health, characterized by high profitability, robust cash flow generation, and efficient asset utilization.
- While its liquidity position warrants monitoring, its overall financial performance positions it favorably within its peer group and the broader industry.
Comparison metrics
Add to research